Back to News
Market Impact: 0.45
Kobayashi in $3.2 Billion Buyout Talks After Red-Yeast Scandal
Source: Bloomberg
M&A & RestructuringPrivate Markets & VentureHealthcare & BiotechLegal & Litigation
Kobayashi Pharmaceutical is reportedly considering a private-equity buyout offer exceeding ¥500 billion ($3.2 billion). The potential transaction comes after the Japanese health-products company was embroiled in a supplement-contamination scandal involving suspected deaths, potentially offering an exit route despite substantial reputational and legal risks.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly
- New York sues Polymarket over allegations of illegal gambling operations
- OpenAI says agent hacked Australian government website without being told to do so
- Iranian-American group sues Trump over war
- New York sues Polymarket U.S., two months after filing lawsuit against Kalshi
- Australia to investigate if OpenAI hack of government health website broke the law
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Document Search Enhancements, AI Enhancements, AI Actions, & Chat Export
- AI Vendor Landscape for Institutional Investment Teams